489 related articles for article (PubMed ID: 35632758)
1. Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies.
Zheng X; Huang Y; Li K; Luo R; Cai M; Yun J
Viruses; 2022 May; 14(5):. PubMed ID: 35632758
[TBL] [Abstract][Full Text] [Related]
2. Beyond Viral Infections: The Multifaceted Roles of Human Papillomavirus and Epstein-Barr Virus in Shaping the Tumor Microenvironment.
Fernandes Q; Sher G; Prabhu KS; Kuttikrishnan S; Merhi M; Dermime S; Junejo K; Bhat AA; Uddin S
Discov Med; 2024 Jan; 36(180):1-15. PubMed ID: 38273742
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma.
Li W; Lv S; Liu G; Lu N; Jiang Y; Liang H; Xia W; Xiang Y; Xie C; He J
Front Immunol; 2023; 14():1124066. PubMed ID: 36860875
[TBL] [Abstract][Full Text] [Related]
4. The Microenvironment in Epstein-Barr Virus-Associated Malignancies.
Tan GW; Visser L; Tan LP; van den Berg A; Diepstra A
Pathogens; 2018 Apr; 7(2):. PubMed ID: 29652813
[TBL] [Abstract][Full Text] [Related]
5. Perspectives for immunotherapy of EBV-associated GLELC: A relatively "hot" tumor microenvironment.
Lei Y; Cao P; Zheng X; Wei J; Cheng M; Liu M
Cancer Med; 2023 Oct; 12(19):19838-19849. PubMed ID: 37732493
[TBL] [Abstract][Full Text] [Related]
6. The immune escape mechanism of nasopharyngeal carcinoma.
Li X; Guo Y; Xiao M; Zhang W
FASEB J; 2023 Jul; 37(7):e23055. PubMed ID: 37358482
[TBL] [Abstract][Full Text] [Related]
7. The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape.
Salnikov MY; MacNeil KM; Mymryk JS
Front Immunol; 2024; 15():1358511. PubMed ID: 38596668
[TBL] [Abstract][Full Text] [Related]
8. Facts and Hopes in the Relationship of EBV with Cancer Immunity and Immunotherapy.
Zhang B; Choi IK
Clin Cancer Res; 2022 Oct; 28(20):4363-4369. PubMed ID: 35686929
[TBL] [Abstract][Full Text] [Related]
9. Immune Evasion by Epstein-Barr Virus.
Ressing ME; van Gent M; Gram AM; Hooykaas MJ; Piersma SJ; Wiertz EJ
Curr Top Microbiol Immunol; 2015; 391():355-81. PubMed ID: 26428381
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy for EBV-associated malignancies.
Gottschalk S; Heslop HE; Rooney CM
Leuk Lymphoma; 2005 Jan; 46(1):1-10. PubMed ID: 15621775
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus (EBV) and its associated human cancers--genetics, epigenetics, pathobiology and novel therapeutics.
Tao Q; Young LS; Woodman CB; Murray PG
Front Biosci; 2006 Sep; 11():2672-713. PubMed ID: 16720343
[TBL] [Abstract][Full Text] [Related]
12. Identifying the key genes of Epstein-Barr virus-regulated tumour immune microenvironment of gastric carcinomas.
Zhou H; Jing S; Liu Y; Wang X; Duan X; Xiong W; Li R; Peng Y; Ai Y; Fu D; Wang H; Zhu Y; Zeng Z; He Y; Ye Q
Cell Prolif; 2023 Mar; 56(3):e13373. PubMed ID: 36519208
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment and RIG-I signaling molecules in Epstein Barr virus-positive and -negative classical Hodgkin lymphoma of the elderly.
Satoh T; Wada R; Yajima N; Imaizumi T; Yagihashi S
J Clin Exp Hematop; 2014; 54(1):75-84. PubMed ID: 24942949
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control
Murer A; Rühl J; Zbinden A; Capaul R; Hammerschmidt W; Chijioke O; Münz C
mBio; 2019 Jan; 10(1):. PubMed ID: 30647153
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic and therapeutic strategies for Epstein-Barr virus-associated diseases: emerging strategies for clinical development.
Dasari V; Sinha D; Neller MA; Smith C; Khanna R
Expert Rev Vaccines; 2019 May; 18(5):457-474. PubMed ID: 30987475
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Cancer Sci; 2008 Aug; 99(8):1633-42. PubMed ID: 18754877
[TBL] [Abstract][Full Text] [Related]
18. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.
Nagpal P; Descalzi-Montoya DB; Lodhi N
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1311. PubMed ID: 33103852
[TBL] [Abstract][Full Text] [Related]
19. Expression of PD-L1 in EBV-associated malignancies.
Li X; Zhang W
Int Immunopharmacol; 2021 Jun; 95():107553. PubMed ID: 33765613
[TBL] [Abstract][Full Text] [Related]
20. Immunity and Immune Evasion Mechanisms of Epstein-Barr Virus.
Yao Y; Kong W; Yang L; Ding Y; Cui H
Viral Immunol; 2023 Jun; 36(5):303-317. PubMed ID: 37285188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
